The Peter Attia Drive - August 23, 2021


#173 - AMA #26: Continuous glucose monitors, zone 2 training, and a framework for interventions

Topics
Hosted by
Guests
Mentioned
#172 - Esther Perel: The effects of trauma, the role of narratives in shaping our worldview, and why we need to accept uncomfortable emotions #174 - Lawrence Wright: The 20th anniversary of the 9⧸11 attacks: reflections on how they happened, and lessons learned and not learned

Episode Stats


Length

19 minutes

Words per minute

180.25

Word count

3,570

Sentence count

233

Harmful content

Toxicity

1

sentences flagged

Hate speech

2

sentences flagged


Summary

Summaries generated with gmurro/bart-large-finetuned-filtered-spotify-podcast-summ .

In this episode, Dr. Bob Kaplan and Dr. Peter Atiyah answer a bunch of follow-up questions to topics covered in the previous AMA. Topics covered in this episode include: - What is the role of drugs in treating diabetes? - What role does exercise play in managing glucose and insulin resistance in diabetics? - Is there a role for exercise in managing insulin resistance? - Should exercise be used in conjunction with diabetes care? - How do we know if exercise interventions are safe and effective? - Are they safe in non-diabetics and non-insulin populations? - Can exercise interventions be helpful in managing diabetes?

Transcript

Transcript generated with Whisper (turbo).
Toxicity classifications generated with s-nlp/roberta_toxicity_classifier .
Hate speech classifications generated with facebook/roberta-hate-speech-dynabench-r4-target .
Topics generated with Qwen2.5-3B-Instruct.
Hosts, guests, and mentioned names generated with spaCy (en_core_web_sm), reconciled against Wikidata.
00:00:00 Hey everyone, welcome to a sneak peek, ask me anything or AMA episode of the drive podcast.
00:00:16 I'm your host, Peter Atiyah. At the end of this short episode, I'll explain how you can
00:00:20 access the AMA episodes in full, along with a ton of other membership benefits we've created,
00:00:25 or you can learn more now by going to peteratiyahmd.com forward slash subscribe.
00:00:31 So without further delay, here's today's sneak peek of the ask me anything episode.
00:00:39 Welcome to ask me anything episode 26. I'm once again joined by Bob Kaplan. In today's episode,
00:00:46 we field a bunch of questions that are kind of follow-up questions to topics we've
00:00:51 recently done deep dives into. The two main themes are more follow-up on CGM and more follow-up on
00:01:00 zone two. Now, when Bob first told me that those were going to be two of the things we're going to
00:01:04 talk about, my first thought was, we have nothing else to say on these topics. We have spent so much
00:01:09 time on them, but it turned out I was wrong. There were a lot of really good questions here
00:01:13 and things I hadn't considered. So if you find yourself wanting on either of those topics,
00:01:18 this episode is definitely for you. If you think you know everything on those,
00:01:22 it's probably still for you. The time of the recording here was in the middle of the Tour de
00:01:26 France. So we had a little digression on performance physiology and cycling. Now, remember if you're a 0.99
00:01:31 subscriber and you want to watch the full video of the podcast, you can find it on the show notes page.
00:01:37 If you're not a subscriber, you can watch a sneak peek of this video on our YouTube page.
00:01:41 So without further delay, I hope you'll enjoy AMA 26.
00:01:48 Hello, Peter.
00:01:52 Hey, Bob. How are you, man?
00:01:54 I'm doing well. How are you?
00:01:56 I'm great.
00:01:57 Okay. You ready for an AMA?
00:01:59 I am. I saw the agenda. It's very aggressive.
00:02:03 Yep. That's how I like it.
00:02:05 Ambitious.
00:02:06 Yes. Yeah. To say the least. I don't know if we'll get through everything,
00:02:10 but we did get a lot of follow-up questions on CGM based on our previous, actually, I think it was
00:02:18 the previous AMA where we talked about glucose. We talked about mean glucose, glucose variability,
00:02:23 and glucose spikes. And then we also had that Sunday email on CGM and non-diabetics. It was
00:02:30 related to a JAMA perspective talking about it. So there's a bunch of questions on that.
00:02:35 Okay.
00:02:36 We also have a couple of questions on Aura, the sleep wearable, the Aura ring. We've got some
00:02:43 exercise-related questions, and we may work in one or two additional questions if we have time.
00:02:49 How does that sound?
00:02:50 I think it sounds like a good list.
00:02:52 Okay. So Peter, since we have a lot of these CGM-related questions, one of the things that
00:02:59 I've heard you talk about is you have a framework for interventions that I think will be really
00:03:03 helpful in laying the foundation for how you think about CGM and their use in different
00:03:08 populations. So can you start off by telling us a little bit about that framework?
00:03:14 Yeah. So again, it doesn't pertain to CGM specifically. It pertains to anything
00:03:19 that comes across my plate. And the first time I actually contemplated this was really when I
00:03:25 started trying to look critically at the data around meditation. So this was probably about
00:03:31 maybe eight to 10 years ago. But anyway, it basically asks a series of questions. So the
00:03:36 first question is, what is the risk of harm from doing this thing? That's a direct question. So if you
00:03:42 do X, how high is the probability of harm? The second question is obviously the contrapositive
00:03:50 of that. If you do X, what is the probability of benefit? And then the third question, and by the
00:03:59 way, before I go to the third question, those first two questions are so obvious that they're almost not
00:04:04 worth stating. And of course that's mirrored in the way the FDA organizes drug trials, right? So a drug
00:04:10 trial is organized first by, well, after you get through the preclinical data, the animal work,
00:04:17 you know, after the IND has been filed, your first trial in humans, which is called a phase one trial
00:04:21 is looking at harm. I mean, it's typically a small trial with dose escalation that is only trying to
00:04:30 understand if as you escalate the dose, do you see an increase in side effects? Very occasionally,
00:04:37 you see some benefits in a phase one trial. And if you do, that's interesting, but you generally
00:04:42 can't take it to the bank because the study is so small and generally it's quite homogeneous.
00:04:47 So that's when you move on to phase two studies, which are geared towards efficacy, i.e. is this thing
00:04:53 doing good? And of course, if the phase two trial is positive, you move to a much larger trial called
00:05:00 a phase three trial, which really doubles down on efficacy. Of course, both of these trials will
00:05:06 continue to be able to pick up any signal of harm. So you're always in the spirit of trying to capture
00:05:11 that. But the real point here is you're raising the bar, so to speak, for what you're demanding of
00:05:16 this. So again, what's the risk of harm? What's the probability of benefit are two obvious questions.
00:05:22 I think the third question then is what's the opportunity cost of this intervention? And I feel
00:05:29 like I've talked about this on a previous podcast before, and maybe it was even one of ours, but
00:05:32 there was this device, sort of a device that you would listen to and it would supposedly put you
00:05:40 in a trance. And the company that was proposing this thing had all sorts of theoretical benefits
00:05:47 from using it. If you listen to this device, you were less likely to get breast cancer and all of
00:05:52 these other things. So was there any harm in this device? As far as I could tell, no, I really didn't
00:05:59 think that listening to this device was harmful in any way. Was there any benefit of this device?
00:06:08 Certainly not to the extent that they made claims. That said, I had tried the device because a friend
00:06:14 of mine bought it for me. And I have to admit, it was the most relaxing thing I'd ever done. In fact,
00:06:19 virtually every time I tried it, I fell asleep. So maybe there was some good in that. Maybe there was
00:06:24 some bad in that if it was a daytime nap and you could speak to the disadvantages of daytime napping,
00:06:29 but there was an opportunity cost to it. And I don't just mean financial. So the device was
00:06:34 pretty expensive. I want to say it was like a thousand bucks if you were going to buy the thing.
00:06:38 Well, a thousand bucks is no trivial sum of money for anyone. So that's obviously something that has
00:06:44 to be weighed against what else could be done with an opportunity cost. But the other thing you have
00:06:48 to keep in mind is their prescription for use was two 20 minute sessions a day, much along the lines
00:06:55 of like transcendental meditation, which is similar, but has much better data. And that's where I kind
00:07:01 of thought, well, there's a problem because for most people who are super busy, 40 minutes a day
00:07:07 for very questionable benefit didn't make a lot of sense if it came at the expense of other things that
00:07:16 undoubtedly had benefit such as, could that be 40 minutes a day of actual meditation? Could that be
00:07:23 40 additional minutes a day of sleep? Could that be 40 minutes a day of exercise? All things that I
00:07:29 would point to as having far greater evidence in favor of. So I think anytime you're thinking about
00:07:36 doing something, you want to kind of go through that. And those are especially important questions to
00:07:43 be asking when the answer is not readily apparent from RCTs that have generally already answered
00:07:52 one and two. Now remember, many RCTs are the easiest RCTs to do are the ones that are based on
00:07:58 pharmacology. And they're generally addressing one and two, but they're not really addressing three
00:08:04 because there really isn't much of an opportunity cost to taking a pill outside of the economic cost.
00:08:09 But the time cost of it is relatively low. Of course, when it comes to RCTs that are more
00:08:15 intervention-based, such as exercise, yes, you want to be able to think about this. But as you look to
00:08:21 something like CGM in the case of non-diabetics, this framework to me is very helpful because at this
00:08:28 time, we don't have great RCTs to point to that say in people who are not yet diabetic, there is a
00:08:36 benefit to using CGM. So again, as you go through that, you ask yourself the question, what is the
00:08:41 risk of harm? And again, when we talk about CGM specifically, I think the risk of harm is very low.
00:08:48 If we were going to speculate what could be harmful about it, well, I think the most obvious thing that
00:08:53 comes to my mind is anxiety that it can stoke, right? It can create obsession in someone. And
00:09:00 certainly I can speak to that personally. I don't think personally I've found it harmful,
00:09:05 but I could absolutely understand it. And I frankly think we have some patients in whom
00:09:10 I've never recommended it. So for example, we have some patients who have a history of eating
00:09:15 disorders. These are patients I would not in any way, shape or form advocate the use of CGM.
00:09:21 I think it's yet another tool that can create a negative cycle around obsession. Is there any chance
00:09:29 of it doing good? Well, I mean, I think I've already made the case for that. I think there's ample
00:09:33 chance for it doing good on two fronts, right? The first front is what I call insight-based good,
00:09:40 which is teaching you what your carbohydrate tolerance is. That's what the tool is for.
00:09:47 And then secondly, what I would call behavioral good or behavior modification, which is effectively
00:09:53 a strapped on version of the Hawthorne effect. So when you're wearing a CGM, you're basically
00:09:59 utilizing a tool that is monitoring you. And there is no shortage of data to support the idea that when
00:10:05 people are asked to monitor food intake, they make changes in the right direction. So if I said to you,
00:10:13 Bob, I want you to record everything you eat for the next month and track it in a food diary,
00:10:20 are you going to make better food choices than you are making now? And the answer is unequivocally,
00:10:25 yes, you are going to do that. Which is also not to pile on, I guess this is the first time I'm
00:10:31 mentioning observational epidemiology so far, at least for this episode. But that's one of the
00:10:36 challenges right there with food frequency questionnaires is that they start asking them
00:10:41 to ask them what foods they're eating or they ask them what foods they ate. And oftentimes just that
00:10:46 by asking, they're changing their behavior. And so you're not really getting an accurate
00:10:50 representation of what they ate previously. Right. So that's a problem that plagues epidemiology,
00:10:56 but you can use that to your advantage. Right. So, you know, and we do that stuff clinically,
00:11:01 right? This is how you create accountability for patients. You say, look, we're going to check in
00:11:07 once a day and I just want you to tell me what you ate. And, and, and even if you provide no other
00:11:14 instruction, which is, oh, I want you to have this many grams of protein and this many grams of carbs
00:11:18 and this many grams of fat. No, no. Even if you don't go to that level, if you just say, I just
00:11:22 want you to tell me what you ate, that level of accountability immediately changes a person's
00:11:26 behavior. And that's an example of how you can use that to your benefit. I guess I'll get to the third
00:11:31 point, which is opportunity costs. So what's the opportunity cost of one of these devices? Well,
00:11:36 I think hands down the biggest opportunity cost is the economic cost. These things are not cheap.
00:11:42 And if you are not diabetic, you are not going to have your insurance company cover one of these
00:11:46 devices. So there are no shortage of companies out there that are repurposing and repackaging
00:11:53 CGM. So there are really three companies that make CGMs in the clinical grade. So there's Medtronic,
00:12:01 Abbott and Dexcom. And again, by way of full disclosure, I consult with Dexcom, not on their CGM
00:12:08 business, but actually on a part of their business that deals with other analytes. So other things that
00:12:14 you could measure. So I actually don't really interact much on the CGM side, but those three
00:12:19 companies make CGMs. And then there are lots of companies like Levels and Super Sapiens that people
00:12:25 have heard of who are plugging in those CGMs into their apps to help users with their goals, be it
00:12:32 weight loss or otherwise. Well, they're not cheap. I'm trying to remember what the cost is. The monthly,
00:12:38 I mean, I feel like the daily cost of CGM is about 10 bucks and there's probably cheaper ways to get
00:12:44 it if you're buying your CGM on eBay or if it's a little bit expired, but directionally speaking,
00:12:48 it's about a $10 a day habit. That adds up, right? But that's, you know, call it $3,500 a year. That's
00:12:54 a huge expense, assuming you need it every minute of every day. And I don't think you do. I think you
00:12:59 can gain a lot of insight using these things periodically. I don't think this is something you
00:13:03 need to be tethered to every minute of every day. There are some people like me who enjoy that.
00:13:08 Not going to lie. I've been wearing CGM for almost six years. It never gets old to me. I continue to
00:13:14 find insights that just provide value. And more than anything else, it's really the behavioral
00:13:20 tool. And that might make me a mental midget. I might just be a guy that is such a simple plebe 0.99
00:13:26 that having that little CGM on my arm is what keeps me away from the ice cream in the freezer,
00:13:31 in the cookies, in the pantry. But if you saw my freezer and you saw my pantry, you would certainly
00:13:36 understand why I stand to benefit from using CGM. I think you mentioned this in the article or the
00:13:42 Sunday post about how the percentages change with when you talk about how much insight you're getting,
00:13:49 say, in the first 30 days versus long-term, whether it's a motivational or a behavioral tool
00:13:54 and how those can shift. But I also want to mention that when I was at UVM, I was getting my undergrad and I
00:13:59 was studying nutrition that, to your point about ice cream in the freezer, I remember for one of our
00:14:06 courses that we were taking, we started doing a food log or a food diary. And I remember at the
00:14:10 time I was eating, I don't know why I got into this, but actually you probably will know why.
00:14:14 I was eating a pint of Ben and Jerry's chocolate chip cookie dough, just religiously.
00:14:19 Is a pint the one that's this big? Like the little one? Is that a pint?
00:14:23 That's the 16-ouncer. Yeah. But I think that's the only thing that Ben and Jerry's comes in.
00:14:29 Okay. Okay. And you were eating one of those a day?
00:14:31 I was eating one of those a day after dinner and it was just like a, yeah, whatever kind of habit.
00:14:37 Then I was doing the food log and I had to keep a food log. And that's how I kicked that. If you
00:14:42 want to call it a habit, that's how I kicked the Ben and Jerry's habit. I said, look, I'm going to
00:14:45 have to write, you know, for the, I think it's two days during the week and one day during the
00:14:49 weekend that I had to do it. And that's, I think, typically what they do for food diaries. And you
00:14:53 just log everything you eat, you know, real time over 24 hours for like a Monday and a Thursday and
00:14:58 a Saturday. And I remember I, I kicked that habit, but it just, it reminds me of this stuff that
00:15:03 some of these things are behavioral tools, maybe in disguise. But I think you mentioned something
00:15:09 like 90, 10 at the beginning with your. Yeah. Yeah. And that, that's sort of what I tell patients.
00:15:13 Cause look, a lot of our patients are like, Hey Peter, what do you think? I mean, do you,
00:15:17 do you think I should do this? And my answer for most of them is, yeah, I think you should.
00:15:20 I think everybody deserves a three month trial of CGM. Again, notwithstanding a handful of patients
00:15:25 who I think have contraindications. And I typically say, look, it's going to start out as about 90,
00:15:31 10, 90% of this is going to be insight. Like you're going to be going, Holy cow. I can't believe
00:15:38 fill in the blank. And only 10% of it is going to be changing your behavior through this Hawthorne effect.
00:15:45 I said, by the end of that 90 days, that's going to flip again. It depends on how much
00:15:50 insight you look to extract, but directionally within about three months, you're going to be
00:15:56 like, you know what? I've sort of figured out the effect of grapes and the difference between like
00:16:01 a grapefruit and a banana. Like I've, I've kind of got that dialed. And I've also figured out that
00:16:06 I can eat a ton of carbs after I work out. But if I eat a ton of carbs before bed,
00:16:12 totally different effect on my blood glucose and over the overnight and in the morning,
00:16:16 but the shift is you start to gamify it a little bit. So yeah, I guess that's sort of what I would
00:16:23 say on, on my framework for how to think about these things. Okay. So a related question to CGM.
00:16:31 I've got, actually, you just mentioned grapes. So this, this person says, my glucose spikes when I
00:16:34 eat some fruits, but not others. Do you know why this happens? And does it mean that I should
00:16:38 avoid fruits that spike my glucose? Thank you for listening to today's sneak peek AMA episode of
00:16:44 the drive. If you're interested in hearing the complete version of this AMA, you'll want to
00:16:48 become a member. We created the membership program to bring you more in-depth exclusive content without
00:16:54 relying on paid ads. Membership benefits are many and beyond the complete episodes of the AMA each
00:17:01 month. They include the following ridiculously comprehensive podcast show notes that detail
00:17:06 every topic, paper, person, and thing we discuss on each episode of the drive access to our private
00:17:12 podcast feed, the qualies, which were a super short podcast, typically less than five minutes
00:17:18 released every Tuesday through Friday, which highlight the best questions, topics, and tactics
00:17:22 discussed on previous episodes of the drive. This is particularly important for those of you who
00:17:28 haven't heard all of the back episodes becomes a great way to go back and filter and decide which ones
00:17:33 you want to listen to in detail, really steep discount codes for products I use and believe
00:17:38 in, but for which I don't get paid to endorse, and benefits that we continue to add over time.
00:17:44 If you want to learn more and access these member-only benefits, head over to
00:17:47 peteratiamd.com forward slash subscribe. Lastly, if you're already a member, but you're hearing this,
00:17:54 it means you haven't downloaded our member-only podcast feed where you can get the full access
00:17:59 to the AMA, and you don't have to listen to this. You can download that at peteratiamd.com
00:18:05 forward slash members. You can find me on Twitter, Instagram, and Facebook, all with the ID
00:18:11 peteratiamd. You can also leave us a review on Apple Podcasts or whatever podcast player you listen on.
00:18:18 This podcast is for general informational purposes only and does not constitute the practice of
00:18:23 medicine, nursing, or other professional healthcare services, including the giving of medical advice.
00:18:29 No doctor-patient relationship is formed. The use of this information and the materials linked to this
00:18:34 podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for
00:18:41 professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining
00:18:48 medical advice from any medical condition they have, and they should seek the assistance of their
00:18:53 healthcare professionals for any such conditions. Finally, I take conflicts of interest very seriously.
00:19:00 For all of my disclosures and the companies I invest in or advise, please visit peteratiamd.com
00:19:07 forward slash about where I keep an up-to-date and active list of such companies.
00:19:18 For all of my disclosures, please visit peteratiamd.com forward slash about where I keep an up-to-date,